Bidding War for the Aesthetic Market's Only Pure Play
Executive Summary
The aesthetic market is becoming somewhat incestuous, with all of its major players current embroiled in some sort of takeover attempt on the businesses of the others. Back in March, dermatology specialist Medicis made an offer to acquire Inamed, the only pure-play in the medical aesthetics market. Some months later, Mentor, Inamed's rival in breast implants, made an offer for Medicis. Now Allergan, "the Botox company," is vying for Inamed with what it believes is a better offer. That all four publicly traded companies are trying to merge with one another highlights just how hot the aesthetics market is today. The bidding war also highlights the unique characteristics of the medical aesthetics specialty, in terms of the blurring between devices and drugs.
You may also be interested in...
Beauty: In the Eye of the Stakeholder
A $12-billion market and growing, the field of aesthetic medicine has exploded with new treatments and techniques for improving and restoring the quality, health and appearance of aging skin. Techniques such as tissue tightening, skin resurfacing, cellulite treatments, dermal augmentation, and fat removal are just some of the new advancements in aesthetic medicine that were highlighted at the 2007 American Academy of Dermatology meeting.
Business & Technology Briefs (01/2007)
A short summary of recent market and product developments in Interventional Cardiology, Spine Surgery, and Aesthetics, including: DES Safety Panel Weighs the Evidence; Percutaneous Lubar Fusion, and New Dermal Fillers.
Deal Statistics Quarterly, Q4 2005
In this issue, we present another installment of our quarterly review of dealmaking-for October-December 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.